Werewolf Therapeutics’ (HOWL) Market Outperform Rating Reiterated at JMP Securities

JMP Securities restated their market outperform rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a report released on Wednesday, Benzinga reports. The brokerage currently has a $12.00 price target on the stock.

A number of other equities research analysts also recently weighed in on HOWL. Wedbush reaffirmed an outperform rating and set a $9.00 price objective on shares of Werewolf Therapeutics in a research report on Monday, June 3rd. HC Wainwright restated a buy rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a report on Wednesday.

Werewolf Therapeutics Trading Down 2.8 %

NASDAQ:HOWL opened at $2.44 on Wednesday. The firm has a 50-day simple moving average of $4.51 and a 200-day simple moving average of $5.09. Werewolf Therapeutics has a one year low of $1.57 and a one year high of $8.19. The firm has a market cap of $106.03 million, a P/E ratio of -2.24 and a beta of 0.62. The company has a debt-to-equity ratio of 0.24, a quick ratio of 6.71 and a current ratio of 6.71.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Friday, May 3rd. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). The business had revenue of $0.74 million during the quarter, compared to the consensus estimate of $5.00 million. Werewolf Therapeutics had a negative return on equity of 36.15% and a negative net margin of 256.33%. Equities analysts anticipate that Werewolf Therapeutics will post -1.52 EPS for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. PFM Health Sciences LP boosted its stake in Werewolf Therapeutics by 35.6% in the 4th quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock worth $13,387,000 after purchasing an additional 909,895 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Werewolf Therapeutics during the first quarter worth $10,922,000. Vanguard Group Inc. grew its holdings in shares of Werewolf Therapeutics by 26.8% during the first quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock valued at $7,176,000 after buying an additional 233,909 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Werewolf Therapeutics by 119.8% in the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock valued at $1,119,000 after acquiring an additional 94,212 shares during the period. Finally, Denali Advisors LLC purchased a new position in Werewolf Therapeutics in the 1st quarter worth $172,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.